X4 Pharmaceuticals Inc (XFOR) - News Archive

BOSTON, February 3, 2025 In a significant move reflecting its commitment to fostering innovation and expertise within the biotech sector, X4 Pharmaceuticals (Nasdaq: XFOR) has announced the issuance of inducement awards...

X4 Pharmaceuticals Reports Promising Phase 2 Results for Mavorixafor in Chronic Neutropenia X4 Pharmaceuticals recently celebrated a significant milestone in their clinical research journey with the announcement of posi...

X4 Pharmaceuticals Expands Team with Inducement Grants: A Strategic Move for GrowthBOSTON, Nov. 1, 2024 In a significant move aimed at bolstering its workforce and enhancing its commitment to addressing rare immune dise...

X4 Pharmaceuticals Achieves Remarkable Results in Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia, Initiates Pivotal Phase 3 CN TrialX4 Pharmaceuticals, a pioneer in the field of rare diseases, has recently...

X4 Pharmaceuticals Continues to Attract Top Talent with Inducement AwardsIn a move to further strengthen its team of experts dedicated to improving the lives of individuals with rare diseases of the immune system, X4 Ph...

In the world of pharmaceutical sciences, breakthrough clinical data from ongoing trials is always eagerly awaited. X4 Pharmaceuticals is set to host a virtual investor event on June 27, 2024, to review the impressive ne...

X4 Pharmaceuticals Secures $125 Million Non-Dilutive Capital to Extend Cash Runway into Late 2025X4 Pharmaceuticals Inc. recently announced a major capital infusion of $125 million, which includes $105 million from the...

X4 Pharmaceuticals, a renowned company dedicated to enhancing the lives of individuals with rare immune system diseases, has recently announced the issuance of inducement awards to new employees. This move is in accorda...

X4 Pharmaceuticals Grants Inducement Awards to New Employees to Drive Innovation in Rare Disease ResearchBOSTON, April 02, 2024 - X4 Pharmaceuticals (Nasdaq: XFOR), a leading company dedicated to improving the lives of...

X4 Pharmaceuticals, a renowned biopharmaceutical company, recently presented additional data from the Phase 2 trial of their drug, Mavorixafor, at the ASH 2023 conference. The accumulated data continue to bolster the ca...